Promising Test Results For Its Cancer Drugs Just Launched This Small Biotech To A Record High
On Monday, the small biotech stock highlighted in today’s article hit a record high, skyrocketing 95.1%. The catalyst?
The Hype And The Data Behind This Breast Cancer Stock’s Massive Surge
The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment.
5 Aggressive Tech Plays Under $10
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
These Biotechs Are Awaiting FDA Rulings In December
November saw the FDA grant its first emergency use approval for an at-home, self-collected nasal swab test for COVID-19 and approve the first drugs for… Read More »These Biotechs Are Awaiting FDA Rulings In December
This Under-The-Radar Biotech’s Unique Approach To Drug Development Could Supercharge Your Portfolio
With potential COVID-19 vaccines and therapeutics garnering most of the attention this year in the biotech space, the biotech stock featured in today’s article, which has “a unique approach to the business of drug development” for genetic diseases, has been flying under the radar.
2 Recommendations For Biotech Upside
Hated stocks and biotech are the best bets right now.
“Solid Upside Potential”: 5 Stocks Trading Under $10 For Very Aggressive Investors
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential.”
Upside Potential Over 100% Have Analysts “Pounding The Table” On These 3 Stocks
Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.
“Explosive Growth Potential”: 2 Under-The-Radar Cancer Drugmakers For Risk-Tolerant Investors
Which developmental-stage biotechs have the potential to beat the difficult odds and successfully get their novel drugs to market?
“The Single Best Investment For The Next Decade”
What is this investment opportunity that seems to check all the boxes?